Stryker Devices Get First-Line US FDA Go-Ahead For Stroke

It’s a first-in-class indication for clot-retrieval devices that the firm gained in a 2011 acquisition.

Stryker Neurovascular TrevoXP 4x20

Stryker Corp.'s Trevo clot-retrieval devices won de novo authorization from US FDA Sept. 2, the first time FDA has OK'd a device as a first-line treatment for ischemic stroke. The devices were developed by Concentric Medical Inc., which was acquired by Stryker for $135m in 2011. (Also see "Stryker Buys Concentric Medical To Enter Acute Ischemic Stroke Market" - Medtech Insight, 5 September, 2011.)

FDA’s move will allow the clot-retrieval devices, known as the Trevo ProVue and XP ProVue retrievers, to be used as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Policy & Regulation

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.